echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Xinrui α-Radiation Cancer Therapy Receives FDA Breakthrough Medical Device Certification

    Xinrui α-Radiation Cancer Therapy Receives FDA Breakthrough Medical Device Certification

    • Last Update: 2021-06-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, Alpha Tau Medical announced that its alpha-radiation cancer therapy Alpha DaRT has obtained the Breakthrough Device Designation granted by the US FDA, which is suitable for the treatment of skin and oral scaly without standard treatments.
    Cell carcinoma
    .

    Breakthrough medical devices are a category designed by the US FDA to accelerate the review process and promote the development of clinical trials of devices for the treatment of life-threatening diseases
    .


    This designation is granted when the device’s preliminary clinical data indicates that it may be more effective than the current standard treatment in terms of clinically significant endpoints of effectiveness, safety or patient quality of life


    Note: The original text has been deleted

    Reference materials:

    [1] Alpha Tau Receives Breakthrough Device Designation from the FDA for Alpha DaRT™.


    Retrieved 2021-06-09, from https:// -from-the-fda-for-alpha-dart-301308178.
    html

    Recently, Alpha Tau Medical announced that its alpha-radiation cancer therapy Alpha DaRT has obtained the Breakthrough Device Designation granted by the US FDA, which is suitable for the treatment of skin and oral scaly without standard treatments.


    Cell carcinoma


    Breakthrough medical devices are a category designed by the US FDA to accelerate the review process and promote the development of clinical trials of devices for the treatment of life-threatening diseases
    .


    This designation is granted when the device’s preliminary clinical data indicates that it may be more effective than the current standard treatment in terms of clinically significant endpoints of effectiveness, safety or patient quality of life


    Note: The original text has been deleted

    Reference materials:

    [1] Alpha Tau Receives Breakthrough Device Designation from the FDA for Alpha DaRT™.


    Retrieved 2021-06-09, from https:// -from-the-fda-for-alpha-dart-301308178.
    html

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.